Concepedia

Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent

Chunxia Liu, Chengye Li, Xingguang Cai, Yuxing Zou, Jiaxian Mo, Bin Chen, Yan Cai, Ting Han, Wenlong Huang, Hai Qian,

Bioorganic Chemistry · 2020 · 19 citations · 14 references

DOI

Concepts

References

14

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · The Lancet · 2018 · 799 citations

, , +17

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Francis S. Willard, Jonathan D. Douros, M Gabe et al. · JCI Insight · 2020 · 487 citations · Full text

, , +17

Gastric emptying and release of incretin hormones after glucose ingestion in humans.

J Schirra, Martin Katschinski, C. Weidmann et al. · Journal of Clinical Investigation · 1996 · 425 citations · Full text

, , +17

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Alessandro Pocai, Paul E. Carrington, Jennifer R. Adams et al. · Diabetes · 2009 · 407 citations · Full text

, , +17

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Elizabeth A. Killion, Jinghong Wang, Junming Yie et al. · Science Translational Medicine · 2018 · 224 citations · Full text

, , +17